Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amphastar Pharmaceuticals, Inc. - Common Stock (NQ:AMPH)

26.78 -0.22 (-0.81%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amphastar Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
3 Russell 2000 Stocks with Questionable Fundamentals
Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resources than their bigger counterparts, these... 
Via StockStory
News headline image
3 Small-Cap Stocks Walking a Fine Line
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a... 
Via StockStory
News headline image
Evolent Health, Amphastar Pharmaceuticals, Iridium, and Magnite Stocks Trade Up, What You Need To Know
A number of stocks jumped in the afternoon session after the major indices rebounded (Nasdaq +2.0%, S&P 500 +2.0%) as President Trump postponed the planned 50% tariff on European Union imports,... 
Via StockStory
Topics Artificial Intelligence Government Stocks
News headline image
Earnings Scheduled For May 7, 2025 ↗
 
Via Benzinga
News headline image
Earnings Outlook For Amphastar Pharma ↗
 
Via Benzinga
News headline image
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2024
Via ACCESS Newswire
News headline image
Earnings Scheduled For February 27, 2025 ↗
 
Via Benzinga
News headline image
Generic Pharmaceuticals Stocks Q1 In Review: Amphastar Pharmaceuticals (NASDAQ:AMPH) Vs Peers
Wrapping up Q1 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amphastar Pharmaceuticals (NASDAQ:AMPH) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
Via ACCESS Newswire
News headline image
AMPHASTAR PHARMACEUTICALS INC (NASDAQ:AMPH) – A Potentially Undervalued Stock Worth Watching ↗
AMPH ASTAR PHARMACEUTICALS INC (NASDAQ:AMPH) offers strong profitability and an undervalued stock price, making it a candidate for value investors. Check the full analysis for details. 
Via Chartmill
News headline image
This Target Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday ↗
 
Via Benzinga
News headline image
Amphastar Pharmaceuticals to Present at the 2025 Bank of America Health Care Conference
Via ACCESS Newswire
News headline image
Amphastar Pharmaceuticals (NASDAQ:AMPH) Misses Q1 Sales Targets
Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) fell short of the market’s revenue expectations in Q1 CY2025, with sales flat year on year at $170.5 million. Its non-GAAP profit of $0.74... 
Via StockStory
News headline image
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025
Via ACCESS Newswire
News headline image
Amphastar Pharmaceuticals Inc (NASDAQ:AMPH): A Closer Look at Dividend Potential ↗
Amphastar Pharmaceuticals Inc (NASDAQ:AMPH): A Closer Look at Dividend Potential 
Via Chartmill
News headline image
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 7th, 2025
Via ACCESS Newswire
News headline image
2 Healthcare Stocks on Our Watchlist and 1 to Be Wary Of
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory... 
Via StockStory
Topics Stocks
News headline image
Generic Pharmaceuticals Stocks Q4 Teardown: Viatris (NASDAQ:VTRS) Vs The Rest
Let’s dig into the relative performance of Viatris (NASDAQ:VTRS) and its peers as we unravel the now-completed Q4 generic pharmaceuticals earnings season. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) is an undervalued gem with solid fundamentals. ↗
Uncover the potential of AMPHASTAR PHARMACEUTICALS IN, an undervalued stock. NASDAQ:AMPH maintains a strong financial position and offers an appealing valuation. 
Via Chartmill
News headline image
2 Safe-and-Steady Stocks with Solid Fundamentals and 1 to Think Twice About
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets. 
Via StockStory
News headline image
2 Reasons to Like AMPH and 1 to Stay Skeptical
What a brutal six months it’s been for Amphastar Pharmaceuticals. The stock has dropped 50.3% and now trades at $24.50, rattling many shareholders. This was partly due to its softer quarterly results... 
Via StockStory
Topics Supply Chain
News headline image
Amphastar Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference
Via ACCESS Newswire
News headline image
International Medication Systems, Ltd. Receives FDA's Drug Shortage Assistance Award
Via ACCESS Newswire
News headline image
AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH), an undervalued stock with good fundamentals. ↗
Take a closer look at AMPHASTAR PHARMACEUTICALS IN , a remarkable value stock. NASDAQ:AMPH excels in fundamentals and maintains a very reasonable valuation. 
Via Chartmill
News headline image
Q4 Earnings Highs And Lows: Amphastar Pharmaceuticals (NASDAQ:AMPH) Vs The Rest Of The Generic Pharmaceuticals Stocks
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at generic pharmaceuticals stocks, starting... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Amphastar Pharmaceuticals to Present at the Barclays 27th Annual Global Healthcare Conference
Via ACCESS Newswire
News headline image
Generic Pharmaceuticals Stocks Q4 In Review: Amneal (NASDAQ:AMRX) Vs Peers
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amneal (NASDAQ:AMRX) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Specialty Pharma Amphastar Stock Falls On Lower Than Expected Q4 Earnings, Analyst Sees Competitive Headwinds ↗
Amphastar's Q4 sales grew 20% to $186.5M, missing estimates. Primatene MIST surpassed $100M in annual sales, while Baqsimi saw strong growth. 
Via Benzinga
News headline image
Amphastar: Earnings Miss, Margins Drop ↗
Amphastar Pharmaceuticals posted modest earnings growth but fell short of market expectations in its latest quarterly results. 
Via The Motley Fool
Topics Earnings
News headline image
Amphastar Pharmaceuticals (NASDAQ:AMPH) Misses Q4 Sales Targets, Stock Drops 12.1%
Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) missed Wall Street’s revenue expectations in Q4 CY2024 as sales rose 4.7% year on year to $186.5 million. Its non-GAAP profit of $0.92 per... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.